Articles de revue sur le mélanome - Dernières paru tions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le mélanome (5 février 2008):

Genetic mutations involved in melanoma: a summary of our current
understanding.
High WA, Robinson WA.
Adv Dermatol. 2007;23:61-79.

Prognostic false-positivity of the sentinel node in melanoma.
Thomas JM.
Nat Clin Pract Oncol. 2008 Jan;5(1):18-23.

Recent discoveries in the genetics of melanoma and their therapeutic
implications.
Marquette A, Bagot M, Bensussan A, Dumaz N.
Arch Immunol Ther Exp (Warsz). 2007 Nov-Dec;55(6):363-72.

Gene expression profiling and clinical outcome in melanoma: in search
of novel prognostic factors.
Winnepenninckx V, van den Oord JJ.
Expert Rev Anticancer Ther. 2007 Nov;7(11):1611-31.

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy
for the treatment of melanoma and other malignancies.
O'Day SJ, Hamid O, Urba WJ.
Cancer. 2007 Dec 15;110(12):2614-27.

Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in
melanomas is silenced by promoter methylation.
McGuinness C, Wesley UV.
Front Biosci. 2008 Jan 1;13:2435-43.

The universal character of the tumor-associated antigen survivin.
Andersen MH, Svane IM, Becker JC, Straten PT.
Clin Cancer Res. 2007 Oct 15;13(20):5991-4.

DNA microarray analyses of melanoma gene expression: a decade in the
mines.
Hoek KS.
Pigment Cell Res. 2007 Dec;20(6):466-84.

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for
the potential treatment of cancer.
Tarhini AA, Kirkwood JM.
Curr Opin Mol Ther. 2007 Oct;9(5):505-14.

The role of integrins in colorectal cancer.
Le Tourneau C, Faivre S, Raymond E.
Oncology (Williston Park). 2007 Aug;21(9 Suppl 3):21-4.

Temozolomide for the treatment of metastatic melanoma: a systematic
review.
Quirt I, Verma S, Petrella T, Bak K, Charette M.
Oncologist. 2007 Sep;12(9):1114-23.


mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor,
radiosensitization and antiangiogenic properties and overview of the
phase I clinical experience.
Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR,
Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park
ES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, De Pass
AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, Dent P,
Senzer N, Nemunaitis JJ, Fisher PB.
Int J Oncol. 2007 Nov;31(5):985-1007.

A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9.
O'Neill GM, Seo S, Serebriiskii IG, Lessin SR, Golemis EA.
Cancer Res. 2007 Oct 1;67(19):8975-9.



(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)